ValuEngine upgraded shares of MediciNova (NASDAQ:MNOV) from a sell rating to a hold rating in a research note released on Wednesday.
Separately, BidaskClub downgraded MediciNova from a buy rating to a hold rating in a research note on Saturday, January 20th.
MediciNova (MNOV) opened at $9.45 on Wednesday. MediciNova has a 12 month low of $4.40 and a 12 month high of $11.45.
TRADEMARK VIOLATION NOTICE: “MediciNova (MNOV) Upgraded by ValuEngine to “Hold”” was published by Sports Perspectives and is the sole property of of Sports Perspectives. If you are viewing this article on another website, it was stolen and republished in violation of U.S. & international copyright and trademark legislation. The legal version of this article can be accessed at https://sportsperspectives.com/2018/02/10/medicinova-mnov-upgraded-by-valuengine-to-hold.html.
Medicinova, Inc is a biopharmaceutical company. The Company focuses on acquiring and developing small molecule therapeutics for the treatment of diseases with unmet medical needs and a commercial focus on the United States market. Its pipeline includes MN-166 (ibudilast), MN-001 (tipelukast), MN-221 (bedoradrine) and MN-029 (denibulin).
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for MediciNova Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MediciNova and related companies with MarketBeat.com's FREE daily email newsletter.